G-1 (CAS 881639-98-1): Selective GPR30 Agonist for Rapid Estrogen Signaling Research

Executive Summary: G-1 is a potent and selective agonist for the G protein-coupled estrogen receptor GPR30/GPER1, with a binding affinity (Ki) of approximately 11 nM and minimal off-target binding to ERα/ERβ at micromolar concentrations (APExBIO product page). Upon G-1 activation, GPR30 mediates rapid, non-genomic estrogen signaling, including PI3K-dependent nuclear PIP3 accumulation and intracellular calcium elevation at EC50 = 2 nM. G-1 inhibits migration in breast cancer lines (SKBr3: IC50 = 0.7 nM; MCF7: IC50 = 1.6 nM) and confers cardioprotective effects in ovariectomized rat heart failure models by restoring adrenergic receptor balance and reducing fibrosis (Wang et al., 2021). APExBIO supplies G-1 as a crystalline solid, soluble in DMSO (≥41.2 mg/mL), and widely utilized for delineating GPR30-mediated pathways across cardiovascular, endocrine, and oncology research.

Biological Rationale

G-1 (CAS 881639-98-1) was developed to probe rapid, non-genomic estrogen signaling mediated by GPR30 (GPER1), distinguishing it from classical nuclear estrogen receptors ERα and ERβ. GPR30 is an integral membrane protein, predominantly localized on the endoplasmic reticulum, that responds to estrogenic ligands with swift intracellular signaling events (Wang et al., 2021). This mechanism is critical in tissues where rapid responses to estrogen drive physiological or pathological outcomes, such as cardiac contractility, immune cell function, and cancer cell migration. Traditional estrogen receptor agonists often lack selectivity, confounding results with nuclear receptor cross-activation. G-1’s high specificity for GPR30 enables unambiguous interrogation of this signaling axis (APExBIO).

Mechanism of Action of G-1 (CAS 881639-98-1), a selective GPR30 agonist

G-1 binds to GPR30/GPER1 with high affinity (Ki ≈ 11 nM) and demonstrates negligible binding to ERα and ERβ at concentrations up to 1 μM (APExBIO). Upon agonist binding, GPR30 undergoes conformational changes that initiate downstream signaling cascades:

• Elevation of Intracellular Calcium: G-1 induces rapid increases in cytosolic Ca²⁺ (EC50 = 2 nM), supporting non-genomic signaling.
• PI3K Pathway Activation: G-1 triggers PI3K-dependent nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), modulating gene expression and cellular metabolism.
• Regulation of Adrenergic Receptors: In cardiac models, G-1 normalizes β1-adrenergic receptor expression and increases β2-adrenergic receptor expression, directly impacting cardiac contractility and fibrosis (Wang et al., 2021).

These effects are distinct from those mediated by ERα or ERβ and are not observed with classical estrogen receptor agonists at equivalent concentrations.

Evidence & Benchmarks

• G-1 selectively activates GPR30 with a binding Ki of ~11 nM, showing <1% activity at ERα or ERβ up to 1 μM (APExBIO).
• G-1 elevates intracellular calcium at EC50 = 2 nM in GPR30-expressing cells (APExBIO).
• In immune models, G-1 restores splenic CD4+ T lymphocyte proliferation and cytokine production following hemorrhagic shock, paralleling the effects of estradiol or ERα agonists, and is abrogated by GPR30 antagonists (Wang et al., 2021).
• Chronic G-1 administration in ovariectomized female Sprague-Dawley rats with heart failure reduces brain natriuretic peptide (BNP), inhibits cardiac fibrosis, and improves contractility through modulation of adrenergic receptor profiles (Wang et al., 2021).
• G-1 suppresses migration in human breast cancer cell lines SKBr3 (IC50 = 0.7 nM) and MCF7 (IC50 = 1.6 nM) via GPR30-mediated signaling (APExBIO).

This article provides mechanistic and translational updates, clarifying the molecular selectivity and in vivo relevance of G-1 beyond the scope of earlier reviews, which primarily focused on immunometabolic modulation. The discussion also extends the strategic context from translational perspectives by quantifying receptor benchmarks and in vivo endpoints in cardiovascular research.

Applications, Limits & Misconceptions

G-1 is utilized in dissecting GPR30-mediated rapid estrogen signaling across cardiovascular, immune, and cancer biology. Its high selectivity enables clear attribution of observed effects to GPR30 activation, eliminating confounds from nuclear receptor cross-talk. In cardiac studies, G-1 helps elucidate mechanisms underlying sex-dimorphic responses to heart failure and fibrosis. In oncology, it serves as a tool to examine migration and invasion pathways in estrogen-responsive tumors.

For further mechanistic insight, see this article, which explores G-1's translational impact in greater depth; the present review updates in vivo benchmarks and practical solubility data for reproducibility.

Common Pitfalls or Misconceptions

• Not a pan-estrogen receptor agonist: G-1 does not activate ERα or ERβ at relevant concentrations; effects are GPR30-specific (APExBIO).
• Solubility constraints: G-1 is insoluble in water and ethanol; experimental solutions require DMSO as solvent with warming or sonication for concentrations above 10 mM (APExBIO).
• Limited in vivo stability: G-1 is not recommended for long-term solution storage; freshly prepared aliquots should be stored at -20°C and used promptly.
• Not effective in ERβ-mediated pathways: Experimental data confirm no effect in models dependent solely on ERβ activation (Wang et al., 2021).
• Species and model specificity: Cardioprotective effects are established in female rat models post-ovariectomy; generalization to other species or sexes requires additional validation.

Workflow Integration & Parameters

G-1 is supplied by APExBIO as a crystalline solid (MW 412.28; C₂₁H₁₈BrNO₃). It should be dissolved in DMSO at ≥41.2 mg/mL for stock solutions. For cell culture or in vivo studies, stock solutions can be prepared at concentrations >10 mM, with mild warming or sonication to enhance dissolution. Avoid water or ethanol as solvents, as G-1 is insoluble in these. Store aliquots at -20°C and avoid repeated freeze-thaw cycles. Solutions are not recommended for storage beyond several weeks.

For dosing in cellular assays, EC50 values for GPR30 activation are in the low nanomolar range (1–10 nM). In animal studies, chronic administration protocols should reference published models (e.g., daily dosing post-ovariectomy in Sprague-Dawley rats). Always include DMSO vehicle controls and titrate to the minimal effective concentration.

To explore advanced protocols for G-1 integration in immunological models, see this resource; this article contributes updated guidance on storage, solubility, and receptor selectivity.

Conclusion & Outlook

G-1 (CAS 881639-98-1), as supplied by APExBIO, represents a gold-standard tool for selective GPR30 activation. It enables precise mechanistic studies and translational research in rapid estrogen signaling, with validated benchmarks across cardiovascular, immune, and cancer models. Its robust selectivity and potency, together with practical handling guidelines, support reproducibility and scalability in laboratory workflows. Future research should address extended species validation, chronic dosing regimens, and combinatorial strategies with other pathway modulators. For ordering and further information, visit the G-1 (CAS 881639-98-1) product page.